Anzeige
Mehr »
Login
Donnerstag, 23.01.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLYX ISIN: US47010C4096 Ticker-Symbol: 1JA2 
Tradegate
21.01.20
16:32 Uhr
0,940 Euro
+0,145
+18,24 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,707
0,730
20:38
0,705
0,730
20:38

Aktuelle News zur JAGUAR HEALTH Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJaguar Health, Inc. - S-1, General form for registration of securities1
08.01.Jaguar Health +14% premarket crofelemer data in IBS-D2
JAGUAR HEALTH Aktie jetzt für 4€ handeln
08.01.Jaguar Health, Inc.: Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome754SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2020 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), today announced that a study appearing in the December 2019 issue of Clinical and Translational...
► Artikel lesen
31.12.19Jaguar Health, Inc. - 8-K, Current Report2
26.12.19Jaguar Health, Inc. - 8-K, Current Report2
16.12.19Jaguar Health, Inc.: Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients763SAN FRANCISCO, CA / ACCESSWIRE / December 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that a clinical research study initiated and sponsored by The University...
► Artikel lesen
10.12.19Jaguar Health, Inc.: Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern735SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals...
► Artikel lesen
21.11.19Jaguar Health, Inc.: Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern894SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals,...
► Artikel lesen
20.11.19Jaguar Health, Inc.: Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine874SAN FRANCISCO, CA / ACCESSWIRE / November 20, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that an article about the Company appears in the Fall 2019 issue of...
► Artikel lesen
14.11.19Jaguar Health down 21% on Mytesi trial continuation4
14.11.19Kadmon Holdings leads healthcare gainers, electroCore and Jaguar Health among losers8
14.11.19Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results260Reminder: Company to Host Investor Call Today at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials...
► Artikel lesen
14.11.19Jaguar Health, Inc.: Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients217SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Georgetown University's Data Safety Monitoring Committee ("DSMC")...
► Artikel lesen
14.11.19Jaguar Health, Inc. - 10-Q, Quaterly Report1
13.11.19Jaguar Health, Inc.: Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy291Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials...
► Artikel lesen
12.11.19Jaguar Health, Inc. - 8-K, Current Report1
12.11.19Jaguar Health, Inc.: Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates224Company Plans to File Q3 2019 10-Q on November 14, 2019 SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company...
► Artikel lesen
30.10.19Jaguar Health, Inc.: Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc.991SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc....
► Artikel lesen
23.10.19Jaguar Health, Inc.: Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea237Napo Pharmaceuticals, Jaguar's Subsidiary, Received Preclinical Services from the National Institute of Allergy and Infectious Diseases for the Studies SAN FRANCISCO, CA / ACCESSWIRE / October 23,...
► Artikel lesen
22.10.19Jaguar Health, Inc. - S-1/A, General form for registration of securities1
Seite:  Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1